NEW YORK, April 29 (GenomeWeb News) - Sirna Therapeutics reported decreased revenues and widening losses for the first quarter on Tuesday.
Revenues for the quarter totaled $318,000, down from $490,000 for the year-ago period.
R&D expenses for the first quarter were $5.1 million, up from $3.8 million during the same quarter last year.
The company's net loss was $5.9 million, or $.19 per share, up from $4.9 million, or $1.62 per share, for the same period last year.
As of March 31, Sirna, based in Boulder, Colo., had $29.6 million in cash, cash equivalents, and securities.